Drug Search Results
More Filters [+]

Pioglitazone

Alternative Names: pioglitazone, actos, ad-4833, pioglitazonhydrochlorid, pioglitazon, sepioglin, actoplus met xr, actoplus met, duetact, oseni, incresync
Latest Update: 2024-07-11
Latest Update Note: Clinical Trial Update

Product Description

Pioglitazone is used with a diet and exercise program and sometimes with other medications, to treat type 2 diabetes (condition in which the body does not use insulin normally and therefore cannot control the amount of sugar in the blood). Pioglitazone is in a class of medications called thiazolidinediones.

Mechanisms of Action: PPAR-g Agonist,STAT5 Inhibitor

Novel Mechanism: No

Modality: Small Molecule

Route of Administration: Oral

FDA Designation: None *

Approval Status: Approved

Approved Countries: Algeria | Argentina | Australia | Austria | Bangladesh | Belgium | Brazil | Bulgaria | Canada | Chile | China | Colombia | Croatia | Czech | Denmark | Dominican Republic | Ecuador | Egypt | Estonia | European Medicines Agency | Finland | Germany | Greece | Hong Kong | Hungary | Iceland | India | Indonesia | Ireland | Israel | Italy | Japan | Jordan | Korea | Latvia | Lebanon | Lithuania | Luxembourg | Malaysia | Mexico | Netherlands | New Zealand | Norway | Pakistan | Peru | Philippines | Poland | Portugal | Romania | Russia | Saudi Arabia | Serbia | Singapore | Slovakia | Slovenia | South Africa | Spain | Sri Lanka | Sweden | Switzerland | Taiwan | Thailand | Tunisia | Turkey | Ukraine | United Arab Emirates | United Kingdom | United States | Uruguay | Venezuela | Vietnam

Approved Indications: General Diabetes | Type 2 Diabetes | General Diabetes | Type 2 Diabetes | General Diabetes | Type 2 Diabetes

Known Adverse Events: Headache | Pharyngitis | Respiratory Tract Infections | Myalgia | Sinusitis | Diarrhea | Edema | Weight Gain

Company: Takeda
Company Location: TOKYO M0 103-8668
Company CEO:
Additonal Commercial Interests: None

Clinical Description

Map of Global Clinical Trials for Pioglitazone

Countries in Clinic: Australia, France, Germany, Korea, Poland, Switzerland, United States

Active Clinical Trial Count: 12

Highest Development Phases

Phase 3: ANCA Vasculitis|Glomerulonephritis|Type 2 Diabetes

Phase 2: COVID-19|Cerebral Hemorrhage|Liposarcoma, Myxoid|Obesity|Polycystic Ovary Syndrome|Uveal Melanoma|Wet Macular Degeneration

Trial

Phase

Trial Status

Disease

Primary Completion Date

Probability of Success

RENATO

P3

Recruiting

Glomerulonephritis|ANCA Vasculitis

2027-04-24

CT-L03-301

P3

Not yet recruiting

Type 2 Diabetes

2026-05-31

2021-003177-58

P2

Active, not recruiting

Polycystic Ovary Syndrome

2025-09-12

ENRICHPLUS

P2

Recruiting

Cerebral Hemorrhage

2025-07-01

Recent News Events